CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+6.92%Year over year
Reported trailing growth
- Revenue
- -7.0%
- EBITDA
- +25.2%
- EBIT
- +22.2%
- EPS
- +34.1%
- Free cash flow
- +2.3%
- Operating cash flow
- +2.4%
Forward estimates
Based on analyst estimates
- Revenue
- -32.5%
- EBITDA
- -1.8%
- EPS
- +1.8%
Three-year CAGR
- Revenue
- +15.4%
- EBITDA
- +0.2%
- EBIT
- -0.6%
- Net income
- -0.9%
- EPS
- +27.4%
- Free cash flow
- -0.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026